Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos MA, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances 2020, 4: 830-844. PMID: 32126144, PMCID: PMC7065476, DOI: 10.1182/bloodadvances.2019000779.Peer-Reviewed Original ResearchConceptsChemotherapy resistanceMultiple myelomaProteasome inhibitorsDouble-refractory multiple myelomaHigh-risk featuresBulk tumor populationOverexpression of MCL1Whole-exome sequencingRefractory patientsImmunomodulatory agentsDisease progressionSame patientNovel treatmentsPatientsKaryotypic eventsEvolution of subclonesMyeloma cellsDrug resistanceMyelomaNovel targetIMiDsTumor populationGene mutationsNext-generation sequencingTP53 pathway